Rewriting Gene Expression Without Rewriting DNA: The Emerging Field of Epigenetic Editing

Key Takeaways

• Epigenome editing targets the regulatory layer that controls gene expression, modifying DNA methylation and chromatin states rather than altering the underlying genetic sequence.

• Many epigenetic editing platforms use catalytically inactive CRISPR proteins, such as dCas9, fused to chromatin-modifying enzymes, allowing precise regulation of transcription at specific genomic loci.

• Systems like CRISPRoff demonstrate that transient exposure to epigenome editors can establish durable epigenetic states that persist across cell divisions.

• Early in vivo studies (including targeted silencing of the Pcsk9 gene in mice) suggest that epigenetic editing may be able to produce sustained physiological effects without introducing double-strand DNA breaks.

• Although significant technical challenges remain, including delivery, specificity, and control of long-term chromatin states, programmable epigenome editing could expand the therapeutic scope of genomic medicine by enabling targeted control of transcriptional programs.

Genome editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR)–Cas systems, have dramatically expanded the ability to manipulate DNA. By introducing targeted breaks in the genome and relying on cellular repair pathways, these systems allow researchers to correct mutations, disrupt genes, or insert new sequences with increasing precision. Over the past decade, CRISPR-based editing platforms have reshaped both basic biological research and the emerging field of genetic medicine.

Simultaneously, a parallel line of research has begun to explore a different strategy for controlling cellular behavior. Rather than modifying DNA sequence directly, these approaches focus on reprogramming gene expression without altering the underlying genome. This emerging field, often referred to as epigenetic editing or epigenome editing, targets the regulatory systems that determine when and how genes are expressed. In this framework, the therapeutic objective shifts from correcting a defective gene sequence to modifying the epigenetic signals that control transcriptional activity.¹

Epigenetic editing works by rewriting regulatory marks, such as DNA methylation or chromatin modifications, at specific genomic loci. Because these marks influence whether genes are active or silent, targeted modification of epigenetic states can activate beneficial genes or repress harmful ones without introducing double-strand DNA breaks or permanently altering genetic sequence. The strategy effectively treats the epigenome as a programmable regulatory layer that can be adjusted to reshape transcriptional programs.

Researchers often describe this approach as a form of “hit-and-run” gene regulation. In many experimental systems, the editing machinery is present only briefly, but the epigenetic state it installs can persist long after the editing components are gone. This property highlights one of the central promises of epigenetic editing: transient interventions that establish durable changes in gene expression.

The implications for therapeutic development are significant. Many diseases arise not from irreversible genetic mutations but from dysregulated gene expression networks. By selectively resetting those regulatory states, epigenetic editing technologies could allow clinicians to correct pathological transcriptional programs without rewriting the genome itself.

Although the DNA sequence provides the fundamental blueprint of the genome, gene activity is governed by a second layer of regulation that determines when and where genes are expressed. This regulatory architecture, collectively referred to as the epigenome, includes mechanisms like DNA methylation and posttranslational modifications (PTMs) of histone proteins. These chemical marks influence chromatin structure and transcriptional accessibility, allowing cells with identical genomes to adopt distinct functional identities.

In normal biology, epigenetic regulation orchestrates processes ranging from embryonic development to tissue differentiation. Patterns of DNA methylation and chromatin modification help establish cell-type–specific gene expression programs and maintain them over time. When these regulatory systems become disrupted, however, the resulting transcriptional changes can contribute to a wide range of diseases, including cancer, metabolic disorders, and neurological conditions. In many cases, pathological states arise not because the DNA sequence itself has changed but because gene expression has been incorrectly activated or suppressed.

Epigenetic editing technologies are designed to intervene at this regulatory level. Instead of altering the genetic code, these systems modify epigenetic marks at specific genomic locations, thereby adjusting transcriptional output. Many platforms accomplish this by directing chromatin-modifying enzymes to targeted DNA sequences using programmable DNA-binding systems derived from CRISPR technologies. By recruiting enzymes that add or remove methyl groups or other chromatin marks, researchers can selectively silence or activate genes with high locus specificity.

This capability introduces the possibility of treating disease by directly rewriting aberrant regulatory states. Rather than correcting every individual mutation that contributes to a disease phenotype, epigenetic editing could allow therapeutic interventions to restore appropriate gene-expression patterns across affected pathways. In this sense, the epigenome functions as a programmable control layer that sits above the genome itself, offering a new point of entry for molecular medicine.

Many of the most widely studied epigenome editing tools build on the same programmable targeting logic that made CRISPR systems transformative for genome editing. In these platforms, the nuclease activity of the Cas protein is disabled, creating a catalytically inactive form known as dead Cas9 (dCas9). While this modified protein can no longer cut DNA, it retains the ability to bind specific genomic sequences directed by a guide RNA. By attaching chromatin-modifying enzymes to dCas9, researchers can recruit regulatory proteins to precise genomic loci and alter local epigenetic states without introducing DNA breaks.

The enzymes fused to dCas9 vary depending on the intended regulatory outcome. Some systems recruit methyltransferases that add DNA methylation marks associated with transcriptional repression, while others deliver demethylases or histone-modifying enzymes that activate transcription. Because targeting is dictated by guide RNAs, the same platform can be reprogrammed to regulate different genes simply by altering the guide sequence. This modular architecture has made CRISPR-derived epigenome editors a versatile platform for manipulating transcriptional programs across many biological contexts.

One of the most influential examples is CRISPRoff, a system designed to install durable gene silencing at specific genomic loci. Rather than simply suppressing transcription temporarily, CRISPRoff deposits DNA methylation and associated chromatin modifications that establish a stable repressive state. Once installed, these epigenetic marks can maintain transcriptional silencing even after the editing machinery is no longer present, effectively creating a programmable form of epigenetic memory.²

This capacity to generate persistent regulatory states distinguishes epigenome editing from conventional transcriptional regulation strategies. Traditional gene-regulation systems typically require continuous presence of transcription factors or regulatory proteins to maintain gene suppression. In contrast, epigenome editors can install chromatin states that remain stable long after the editing machinery has disappeared.

Experimental studies with CRISPRoff illustrate this principle clearly. Transient expression of the editing system is sufficient to initiate DNA methylation patterns that remain stable through repeated rounds of cell division. The resulting repressive chromatin environment continues to suppress transcription as cells proliferate or differentiate into new lineages, converting short-lived molecular interventions into long-term transcriptional programs.²

From a therapeutic perspective, this property could significantly influence how gene-regulation therapies are designed. Instead of requiring sustained expression of regulatory proteins or repeated administration of gene-modulating agents, transient delivery of an epigenome editor could be used to establish a durable transcriptional state. In principle, a single intervention might reset pathological gene-expression programs and maintain that correction over extended periods.

While early demonstrations of epigenome editing focused largely on cell culture systems, more recent studies have shown that these approaches can function in living organisms. Experiments in animal models are beginning to test whether programmable chromatin editing can modify disease-relevant genes in vivo and produce sustained physiological effects.

One example involves targeted epigenome editing of the Pcsk9 gene, which encodes a protein that regulates circulating cholesterol levels by controlling the degradation of low-density lipoprotein (LDL) receptors in the liver. Because inhibition of PCSK9 has already proven to be an effective strategy for lowering cholesterol, the gene provides a useful test case for evaluating therapeutic epigenetic silencing. In mouse experiments, researchers delivered an epigenome editing system designed to deposit repressive chromatin marks at the Pcsk9 locus, leading to durable suppression of gene expression.³

The intervention resulted in sustained reductions in circulating PCSK9 protein levels, demonstrating that epigenetic editing could produce measurable physiological effects in vivo. Importantly, the silencing occurred without permanent modification of the underlying DNA sequence. Instead of introducing double-strand breaks or altering genomic structure, the system relied on epigenetic mechanisms to establish a transcriptionally repressed state at the targeted gene.³

These experiments illustrate how epigenome editing could function as a “hit-and-run” therapeutic strategy. By installing repressive chromatin states that persist after the editing machinery has cleared, a transient intervention can generate durable changes in gene expression. The Pcsk9 studies ARE an early demonstration that programmable epigenetic silencing can operate in living organisms and produce sustained biological outcomes without conventional genome editing.

The development of epigenome editing technologies has prompted researchers to reconsider the conceptual boundaries of gene therapy. Traditional genome editing strategies focus on modifying DNA sequence, typically by correcting mutations, inserting new genetic material, or disrupting specific genes. Epigenetic editing approaches pursue a different objective: regulating transcriptional activity without altering the underlying genetic code.

In this framework, the therapeutic target shifts from DNA sequence to the regulatory systems that control gene expression. By modifying epigenetic marks, such as DNA methylation or chromatin structure, these technologies can influence whether specific genes are active or silent. Instead of introducing permanent genomic changes, the intervention adjusts the transcriptional state of a gene by reshaping its epigenetic environment.⁴

This distinction has important implications for the types of diseases that might be addressed through genomic medicine. While some disorders arise from single gene mutations that are suitable targets for sequence correction, many others involve complex disruptions in gene regulation. Conditions like cancer, metabolic disorders, and certain neurological diseases often reflect widespread transcriptional dysregulation rather than a single defective gene. In such cases, the ability to selectively modulate gene expression could provide a more flexible therapeutic strategy.

Because epigenetic editing technologies operate at the level of gene regulation, some researchers view them as an extension of gene therapy that focuses on controlling transcription rather than rewriting the genome itself. By enabling precise manipulation of transcriptional programs, these approaches could expand the range of diseases that genomic medicine is capable of addressing.

Although therapeutic development is a major driver of interest in epigenome editing, these technologies are also becoming powerful tools for studying fundamental biological processes. Because epigenetic marks play a central role in regulating cell identity, development, and aging, the ability to modify these marks at specific genomic locations provides researchers with a way to directly test how epigenetic states influence cellular function.

One emerging area of investigation involves the relationship between epigenetic regulation and biological aging. Aging is associated with characteristic changes in DNA methylation patterns across the genome, often described as an “epigenetic clock.” Researchers have begun to explore whether targeted epigenetic editing can manipulate these methylation patterns and thereby influence broader regulatory networks associated with aging. In one study, editing individual age-associated CpG sites altered not only local methylation states but also affected genome-wide epigenetic signatures linked to aging.⁵

These findings suggest that targeted epigenetic interventions may be capable of influencing complex regulatory systems rather than only isolated genes. By selectively modifying specific epigenetic sites, researchers can observe how local changes propagate through wider gene-regulatory networks. This capacity to experimentally reshape chromatin states provides a new experimental framework for probing the causal relationships between epigenetic regulation and physiological processes.

As epigenome editing technologies continue to mature, their value as research tools may prove just as significant as their therapeutic potential. The ability to install, erase, or rewrite epigenetic marks with high precision allows scientists to explore how gene regulatory programs operate in living systems and how those programs change during development, aging, and disease.

Despite rapid progress in the development of epigenome editing technologies, several technical barriers must be addressed before these approaches can be widely deployed as therapeutic tools. Many of the challenges parallel those faced by earlier genome editing platforms, but they are complicated by the additional requirement of controlling complex chromatin states rather than simply modifying DNA sequence.

One of the most important issues involves achieving consistent target specificity. Epigenome editors typically rely on programmable DNA-binding systems, such as dCas9 guided by RNA sequences, to direct chromatin-modifying enzymes to particular genomic loci. Although this targeting strategy can provide high precision, off-target binding remains a concern, particularly when the attached effector enzymes are capable of modifying chromatin structure. Even modest levels of off-target activity could potentially alter gene expression at unintended loci, making careful evaluation of specificity essential for therapeutic applications.⁶

Another challenge lies in establishing epigenetic states that are both stable and controllable. While one of the advantages of epigenome editing is the ability to create durable transcriptional programs, excessive persistence could also present risks if an unintended regulatory state becomes locked in place. Researchers therefore continue to investigate ways to design editing systems that produce stable regulatory outcomes while retaining the possibility of reversing or adjusting those states when necessary.

Delivery represents an additional major obstacle. Many epigenome editing systems involve relatively large molecular complexes composed of Cas-derived targeting proteins and chromatin-modifying enzymes. Efficiently delivering these components into specific tissues or cell types remains a significant challenge, particularly for in vivo applications. Advances in delivery technologies, including viral vectors and lipid nanoparticle systems, will likely play a central role in determining whether epigenome editing platforms can transition from experimental demonstrations to practical clinical therapies).

Continued progress in targeting accuracy, delivery strategies, and the design of controllable regulatory systems will be necessary to fully realize the therapeutic potential of epigenetic editing technologies.

Epigenetic editing represents a shift in how researchers think about intervening in the genome. Instead of focusing solely on altering DNA sequence, these approaches aim to reset the regulatory systems that determine how genes are expressed. By modifying epigenetic marks that govern transcriptional activity, epigenome editing technologies offer a way to influence cellular behavior without permanently rewriting the genetic code.

The research described throughout this field demonstrates that targeted chromatin modifications can produce durable changes in gene expression, even when the editing machinery itself is present only briefly. Systems like CRISPR-based epigenome editors have shown that transcriptional programs can be installed, maintained, and potentially reversed through precise manipulation of epigenetic states. These capabilities suggest that gene regulation itself can become a programmable therapeutic target.

If these technologies can be translated successfully into clinical settings, they may expand the scope of genomic medicine beyond sequence correction. Many diseases arise from dysregulated gene expression networks rather than single genetic mutations, and epigenetic editing offers a way to address those regulatory disturbances directly. In this sense, epigenome editing could complement conventional genome editing by providing an additional layer of intervention focused on transcriptional control.

The field remains in its early stages, and significant technical challenges must still be overcome. Nonetheless, the core idea is already reshaping how scientists approach genetic medicine. By treating the epigenome as a programmable regulatory system, researchers are beginning to explore therapeutic strategies that modify how genes behave rather than altering the DNA sequences themselves.

1. Heller, Elizabeth A, Lacramioara Bintu, and Marianne G Rots. “Epigenetic editing: from concept to clinic.” Nature Reviews Drug Discovery. 25: 227–248 (2025).

2. Nuñez, James K, et al. “Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing.” Cell. 184: 2503–2519.e17 (2021).

3. Cappelluti, Martino Alfredo, et al. “Durable and efficient gene silencing in vivo by hit-and-run epigenome editing.” Nature. 627: 416–423 (2024).

4. Whitten, Allison. “Epigenetic editing expands the reach of gene therapy.” Drug Discovery News. 3 Jun. 2025.

5. Liesenfelder, Sven, et al. “Epigenetic editing at individual age-associated CpGs affects the genome-wide epigenetic aging landscape.” Nature Aging. 5: 997–1009 (2025).

6. Roth, Goldie V, Isabella R Gengaro, and Lei S Qi. “Precision epigenetic editing: Technological advances, enduring challenges, and therapeutic applications.” Cell Chemical Biology. 31: 1422–1446 (2024).